Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

Diastolic Dysfunction with Normal Heart T2* in Thalassemia Major with Heart Failure. a Single Centre Study

Luigi Mancuso, MD, Angela Vitrano, PhD, Massimiliano Sacco, Dr, Andrea Mancuso, MD, Antonietta Ledda, MD, Aurelio Maggio, MD

Blood (2016) 128 (22): 2457.

https://doi.org/10.1182/blood.V128.22.2457.2457

Published: 2016

Journal Articles

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Hongming Zhu, Jiong Hu, Li Chen, Wei Zhou, Xiaoyang Li, Wang Lining, Xia Zhao, Yunxiang Zhang, Huijin Zhao, Yu Chen, Huiping Sun, Qiusheng Chen, Yu Chen, Weili Zhao, Jianqing Mi, Zhixiang Shen, Saijuan Chen, Zhenyi Wang, Junmin Li, MD PhD

Blood (2014) 124 (21): 282.

https://doi.org/10.1182/blood.V124.21.282.282

Published: 2014

Journal Articles

Mechanistic Insights Into Ventricular Arrhythmias Associated With Sickle Cell Disease: Role Of Abnormal Repolarization

I D Greener, Ph.D., C A Rutledge, BS, T Abassi, BS, K Yadav, BS, A B Desai, MD, M Oberoi, MD, P Chunduru, MD, D P Parikh, MD, J GN Garcia, MD, Victor R. Gordeuk, MD, Cheryl A. Hillery, MD, S c Dudley, Jr., MD, Roberto F Machado, MD, A A Desai, MD

Blood (2013) 122 (21): 980.

https://doi.org/10.1182/blood.V122.21.980.980

Published: 2013

Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD

Blood (2013) 122 (21): 4820.

https://doi.org/10.1182/blood.V122.21.4820.4820

Published: 2013

Journal Articles

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Bengt I Eriksson, MD, John J Smith, MD, PhD, Joseph Caprini, MD, Stefan Hantel, PhD, Andreas Clemens, MD, Martin Feuring, MD, Gregory W Barsness, MD

Blood (2011) 118 (21): 2309.

https://doi.org/10.1182/blood.V118.21.2309.2309

Published: 2011

Journal Articles

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

Sam A Ruell, RN, Miles Prince, MD, FRACP, FRCPA, Hang Quach, MBBS, FRACP, FRCPA, MD, Emma Link, PhD, Joanne Dean, Simon J. Harrison, MD, PhD

Blood (2010) 116 (21): 5037.

https://doi.org/10.1182/blood.V116.21.5037.5037

Published: 2010

Journal Articles

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Christopher Cabell, M.D., M.H.S., F.A.C.C., Susan Bates, MD, Richard Piekarz, MD, PhD, Sean Whittaker, MD, FRCP, Youn H Kim, MD, Michelle Currie, C. J Godfrey, Ph.D., Christopher Schoonmaker, Ph.D., Jean Nichols, PhD, Darrell Nix, Ph.D., Howard A. Burris, MD

Blood (2009) 114 (22): 3709.

https://doi.org/10.1182/blood.V114.22.3709.3709

Published: 2009

Journal Articles

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Susan Bates, MD, Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, William Douglas Figg, Sr., PharmD, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRAPC, Mark Kirschbaum, MD, John P. Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Maryalice Stetler- Stevenson, MD, PhD, Alex Ling, MD, Jean Nichols, PhD

Blood (2008) 112 (11): 1568.

https://doi.org/10.1182/blood.V112.11.1568.1568

Published: 2008

Journal Articles

A Phase I–II Study To Determine the Maximum Tolerated Infusion-Rate of Rituximab, with a Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function.

Marco Siano, M.D., Erika Lerch, M.D., Emanuele Zucca, M.D., Oreste Mora, M.D., Cristiana Sessa, M.D., Michele Ghielmini, MD

Blood (2007) 110 (11): 3411.

https://doi.org/10.1182/blood.V110.11.3411.3411

Published: 2007

Journal Articles

Electrocardiographic Screening for Cardiac Iron in Thalassemia Major.

Jon A. Detterich, MD, Janelle Miller, BS, Thomas D. Coates, MD, PhD, John C. Wood, MD, PhD

Blood (2007) 110 (11): 2766.

https://doi.org/10.1182/blood.V110.11.2766.2766

Published: 2007

Journal Articles

Stem Cell Transplantation in Patients with Preexisting Coronary Artery Disease.

George Chen, MD, George Carrum, MD, Uday Popat, MD

Blood (2004) 104 (11): 5028.

https://doi.org/10.1182/blood.V104.11.5028.5028

Published: 2004

Journal Articles

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

Dilip Unnikrishnan, Janice P. Dutcher, Nikita Varshneya, Richard Lucariello, Marietta Api, Susan Garl, Peter H. Wiernik, Salvatore Chiaramida

Blood (2001) 97 (5): 1514–1516.

https://doi.org/10.1182/blood.V97.5.1514

Published: 2001

NARROW

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Diastolic Dysfunction with Normal Heart T2* in Thalassemia Major with Heart Failure. a Single Centre Study

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Mechanistic Insights Into Ventricular Arrhythmias Associated With Sickle Cell Disease: Role Of Abnormal Repolarization

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

A Phase I–II Study To Determine the Maximum Tolerated Infusion-Rate of Rituximab, with a Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function.

Electrocardiographic Screening for Cardiac Iron in Thalassemia Major.

Stem Cell Transplantation in Patients with Preexisting Coronary Artery Disease.

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only